Felipe Garcia

List of Publications by Year
in descending order

328 papers	14,731 citations	30070 54 h-index	29157 104 g-index
351 all docs	351 docs citations	351 times ranked	19699 citing authors

#	Article	IF	Citations
1	Repurposed Antiviral Drugs for Covid-19 â€" Interim WHO Solidarity Trial Results. New England Journal of Medicine, 2021, 384, 497-511.	27.0	2,014
2	Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. New England Journal of Medicine, 2021, 384, 1503-1516.	27.0	762
3	Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clinical Microbiology and Infection, 2021, 27, 83-88.	6.0	636
4	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	7.4	498
5	The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. Aids, 2010, 24, 123-137.	2.2	360
6	COVID-19 in patients with HIV: clinical case series. Lancet HIV,the, 2020, 7, e314-e316.	4.7	350
7	Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. Aids, 1999, 13, F79-F86.	2.2	235
8	Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13747-13752.	7.1	199
9	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 522-532.	10.7	195
10	A Dendritic Cellâ€"Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication. Science Translational Medicine, 2013, 5, 166ra2.	12.4	193
11	The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. Aids, 2001, 15, F29-F40.	2.2	160
12	Long-Term CD4+ T-Cell Response to Highly Active Antiretroviral Therapy According to Baseline CD4+ T-Cell Count. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 702-713.	2.1	156
13	A Prospective Trial of Structured Treatment Interruptions in Human Immunodeficiency Virus Infection. Archives of Internal Medicine, 2003, 163, 1220.	3.8	153
14	Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. Aids, 2006, 20, 59-66.	2.2	153
15	Therapeutic Immunization with Dendritic Cells Loaded with Heatâ€Inactivated Autologous HIVâ€1 in Patients with Chronic HIVâ€1 Infection. Journal of Infectious Diseases, 2005, 191, 1680-1685.	4.0	147
16	Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.5	145
17	Measuring quality of life among people living with HIV: a systematic review of reviews. Health and Quality of Life Outcomes, 2017, 15, 220.	2.4	130
18	Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV,the, 2021, 8, e294-e305.	4.7	129

#	Article	IF	Citations
19	HIV and Syphilis: When to Perform a Lumbar Puncture. Sexually Transmitted Diseases, 2007, 34, 141-144.	1.7	124
20	Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study. Clinical Infectious Diseases, 2004, 38, 565-571.	5.8	118
21	mHealth Interventions To Support Self-Management In HIV: A Systematic Review. Open AIDS Journal, 2017, 11, 119-132.	0.5	113
22	Plasma Stromal Cellâ€“Derived Factor (SDF)â€1 Levels, SDF1â€3â€²A Genotype, and Expression of CXCR4 on T Lymphocytes: Their Impact on Resistance to Human Immunodeficiency Virus Type 1 Infection and Its Progression. Journal of Infectious Diseases, 2002, 186, 922-931.	4.0	110
23	Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Medicine, 2007, 8, 251-258.	2.2	110
24	Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Lancet, The, 1998, 352, 1194-1195.	13.7	109
25	Variable Impact on Mortality of AIDSâ€Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDSâ€Defining Conditions Are Created Equal. Clinical Infectious Diseases, 2009, 48, 1138-1151.	5.8	108
26	A nosocomial outbreak of influenza during a period without influenza epidemic activity. European Respiratory Journal, 2003, 21, 303-307.	6.7	105
27	A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection. Journal of Infectious Diseases, 2011, 203, 473-478.	4.0	105
28	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4Ã—: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2014, 14, 291-300.	9.1	100
29	Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens. Diagnostic Microbiology and Infectious Disease, 2006, 56, 153-160.	1.8	98
30	Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. Aids, 2020, 34, 1775-1780.	2.2	97
31	Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. Aids, 2000, 14, 1921-1933.	2.2	82
32	Current and Promising Pharmacotherapies, and Novel Research Target Areas in the Treatment of Alcohol Dependence: A Review. Current Pharmaceutical Design, 2011, 17, 1323-1332.	1.9	74
33	Effect of Mycophenolate Mofetil on Immune Response and Plasma and Lymphatic Tissue Viral Load During and After Interruption of Highly Active Antiretroviral Therapy for Patients With Chronic HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 823-830.	2.1	71
34	A New Multidisciplinary Home Care Telemedicine System to Monitor Stable Chronic Human Immunodeficiency Virus-Infected Patients: A Randomized Study. PLoS ONE, 2011, 6, e14515.	2.5	71
35	Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine, 2011, 29, 8309-8316.	3.8	70
36	Rate and predictors of progression in elite and viremic HIV-1 controllers. Aids, 2016, 30, 1209-1220.	2.2	69

#	Article	IF	Citations
37	Increased CSF levels of IL-1Î², IL-6, and ACE in SARS-CoV-2â€“associated encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	69
38	Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV,the, 2021, 8, e701-e710.	4.7	69
39	Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet, The, 2004, 364, 65-67.	13.7	65
40	Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. Aids, 2018, 32, 2533-2545.	2.2	65
41	The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens. Journal of Virology, 2011, 85, 11468-11478.	3.4	63
42	Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication. Aids, 1999, 13, 1491-1496.	2.2	62
43	HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma. Modern Pathology, 2017, 30, 745-760.	5.5	60
44	Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells. Journal of Leukocyte Biology, 2010, 89, 127-136.	3.3	59
45	Coronavirus Disease 2019 in Pregnancy: A Clinical Management Protocol and Considerations for Practice. Fetal Diagnosis and Therapy, 2020, 47, 519-528.	1.4	59
46	Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. Clinical Infectious Diseases, 2012, 54, 1364-1372.	5.8	58
47	Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection. Journal of Virology, 2018, 92, .	3.4	58
48	Manic Syndrome Associated with Efavirenz Overdose. Clinical Infectious Diseases, 2001, 33, 270-271.	5.8	57
49	Dendritic cell based vaccines for HIV infection. Human Vaccines and Immunotherapeutics, 2013, 9, 2445-2452.	3.3	57
50	Definition of Advanced Age in HIV Infection: Looking for an Age Cut-Off. AIDS Research and Human Retroviruses, 2012, 28, 1000-1006.	1.1	56
51	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. Journal of Antimicrobial Chemotherapy, 2015, 70, 1833-1842.	3.0	56
52	Clinical, Virologic, and Immunologic Response to Efavirenz-or Protease Inhibitor???Based Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive Patients With Advanced HIV Infection (EfaVIP 2 Study). Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 343-350.	2.1	55
53	Therapeutic vaccines against HIV infection. Human Vaccines and Immunotherapeutics, 2012, 8, 569-581.	3.3	55
54	Immunometabolism is a key factor for the persistent spontaneous elite control of HIV-1 infection. EBioMedicine, 2019, 42, 86-96.	6.1	55

#	Article	IF	Citations
55	Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors and Prevalence of HIV Type 1 Non-B Subtypes Are Increasing among Persons with Recent Infection in Spain. Clinical Infectious Diseases, 2005, 41, 1350-1354.	5.8	53
56	Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients. Aids, 2013, 27, 181-189.	2.2	53
57	Development of an mHealth platform for HIV Care: Gathering User Perspectives Through Co-Design Workshops and Interviews. JMIR MHealth and UHealth, 2018, 6, e184.	3.7	53
58	Human immature monocyte-derived dendritic cells produce and secrete Î±-defensins 1â€“3. Journal of Leukocyte Biology, 2007, 82, 1143-1146.	3.3	52
59	Decrease in Serial Prevalence of Coinfection with Hepatitis C Virus among HIVâ€Infected Patients in Spain, 1997â€“2006. Clinical Infectious Diseases, 2009, 48, 1467-1470.	5.8	52
60	Differential MicroRNA Expression Profile between Stimulated PBMCs from HIV-1 Infected Elite Controllers and Viremic Progressors. PLoS ONE, 2014, 9, e106360.	2.5	52
61	Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. Aids, 2008, 22, 2461-2469.	2.2	51
62	Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001-2009. AIDS Research and Therapy, 2011, 8, 22.	1.7	50
63	Pneumocystispneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients. Expert Review of Anti-Infective Therapy, 2019, 17, 787-801.	4.4	49
64	Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. Diagnostic Microbiology and Infectious Disease, 2008, 62, 34-43.	1.8	47
65	Immunological Profile of Heterosexual Highly HIVâ€Exposed Uninfected Individuals: Predominant Role of CD4 and CD8 Tâ€Cell Activation. Journal of Infectious Diseases, 2007, 196, 1191-1201.	4.0	46
66	Phenotype and functional analysis of human monocytes-derived dendritic cells loaded with a carbosilane dendrimer. Biomaterials, 2010, 31, 8749-8758.	11.4	46
67	A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions. Aids, 2003, 17, 43-51.	2.2	45
68	Discontinuation of Primary and SecondaryToxoplasma gondiiProphylaxis Is Safe in HIVâ€Infected Patients after Immunological Restoration with Highly Active Antiretroviral Therapy: Results of an Open, Randomized, Multicenter Clinical Trial. Clinical Infectious Diseases, 2006, 43, 79-89.	5.8	44
69	Central nervous system opportunistic infections in developed countries in the highly active antiretroviral therapy era. Journal of NeuroVirology, 2005, 11, 72-82.	2.1	44
70	Immunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistence. Modern Pathology, 2005, 18, 127-136.	5.5	43
71	Educational Gradient in HIV Diagnosis Delay, Mortality, Antiretroviral Treatment Initiation and Response in a Country with Universal Health Care. Antiviral Therapy, 2012, 17, 1-8.	1.0	43
72	Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands. Biomaterials, 2016, 75, 327-339.	11.4	43

#	Article	IF	Citations
73	A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. Aids, 1999, 13, 2377-2388.	2.2	42
74	Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 339-351.	3.3	42
75	Most HIV Type 1 Non-B Infections in the Spanish Cohort of Antiretroviral Treatment-NaÃ¯ve HIV-Infected Patients (CoRIS) Are Due to Recombinant Viruses. Journal of Clinical Microbiology, 2012, 50, 407-413.	3.9	41
76	PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia. PLoS Pathogens, 2015, 11, e1005270.	4.7	41
77	Risk of Selecting De Novo Drug-Resistance Mutations during Structured Treatment Interruptions in Patients with Chronic HIV Infection. Clinical Infectious Diseases, 2005, 41, 883-890.	5.8	40
78	Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. Aids, 2011, 25, 27-36.	2.2	40
79	Impact of low serum calcium at hospital admission on SARS-CoV-2 infection outcome. International Journal of Infectious Diseases, 2021, 104, 164-168.	3.3	40
80	Increased Î±-Defensins 1-3 Production by Dendritic Cells in HIV-Infected Individuals Is Associated with Slower Disease Progression. PLoS ONE, 2010, 5, e9436.	2.5	40
81	Viral load in asymptomatic patients with CD4+ lymphocyte counts above 500 Ã— 106/l. Aids, 1997, 11, 53-57.	2.2	39
82	Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study. Aids, 2000, 14, 2485-2494.	2.2	39
83	Reappraisal of the aetiology and prognostic factors of severe acute respiratory failure in HIV patients. European Respiratory Journal, 2001, 17, 87-93.	6.7	39
84	Inequalities in <scp>HIV</scp> disease management and progression in migrants from <scp>L</scp>atin <scp>A</scp>merica and subâ€<scp>S</scp>aharan <scp>A</scp>frica living in <scp>S</scp>pain. HIV Medicine, 2013, 14, 273-283.	2.2	39
85	Rate and Predictors of Non-AIDS Events in a Cohort of HIV-Infected Patients with a CD4 T Cell Count Above 500 Cells/mm³. AIDS Research and Human Retroviruses, 2013, 29, 1161-1167.	1.1	39
86	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. Vaccine, 2011, 29, 5250-5259.	3.8	38
87	Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab. Nature Communications, 2019, 10, 3705.	12.8	38
88	Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix). Aids, 2017, 31, 321-332.	2.2	38
89	The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: A prospective cohort study. Liver Transplantation, 2009, 15, 1133-1141.	2.4	37
90	Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients. Aids, 2010, 24, 2029-2039.	2.2	37

#	Article	IF	Citations
91	Broadly Cross-Neutralizing Antibodies in HIV-1 Patients with Undetectable Viremia. Journal of Virology, 2011, 85, 5804-5813.	3.4	37
92	Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. Aids, 2009, 23, 2485-2495.	2.2	36
93	Personalized Therapy Approach for Hospitalized Patients with Coronavirus Disease 2019. Clinical Infectious Diseases, 2022, 74, 127-132.	5.8	36
94	Infective endocarditis not related to intravenous drug abuse in HIV-1-infected patients: report of eight cases and review of the literature. Clinical Microbiology and Infection, 2003, 9, 45-54.	6.0	35
95	Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain. Lancet Regional Health - Europe, The, 2021, 3, 100041.	5.6	35
96	Relevance of HIV-1-Specific CD4+ Helper T-Cell Responses During Structured Treatment Interruptions in Patients With CD4+ T-Cell Nadir Above 400/mm3. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 791-799.	2.1	34
97	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. International Journal of Epidemiology, 2012, 41, 1807-1820.	1.9	34
98	In vitro effects of the CCR5 inhibitor maraviroc on human T cell function. Journal of Antimicrobial Chemotherapy, 2013, 68, 577-586.	3.0	34
99	Analysis of Non-AIDS-Defining Events in HIV Controllers. Clinical Infectious Diseases, 2016, 62, 1304-1309.	5.8	34
100	HIV-1 infected patients older than 50 years. PISCIS cohort study. Journal of Infection, 2008, 57, 64-71.	3.3	33
101	HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses. Journal of Virology, 2015, 89, 9189-9199.	3.4	33
102	Group A Streptococcal Infections in Injection Drug Users in Barcelona, Spain. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30	1.0	32
103	Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort. HIV Medicine, 2019, 20, 237-247.	2.2	32
104	Unintended HIV-1 Infection During Analytical Therapy Interruption. Journal of Infectious Diseases, 2020, 221, 1740-1742.	4.0	32
105	Dendritic Cells Exposed to MVA-Based HIV-1 Vaccine Induce Highly Functional HIV-1-Specific CD8+ T Cell Responses in HIV-1-Infected Individuals. PLoS ONE, 2011, 6, e19644.	2.5	32
106	Selective Induction of Host Genes by MVA-B, a Candidate Vaccine against HIV/AIDS. Journal of Virology, 2010, 84, 8141-8152.	3.4	31
107	Association of microbial translocation biomarkers with clinical outcome in controllers HIV-infected patients. Aids, 2015, 29, 675-681.	2.2	31
108	iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials, 2019, 20, 361.	1.6	31

#	Article	IF	Citations
109	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. Aids, 2012, 26, 1691-1705.	2.2	31
110	Residual Low-Level Viral Replication Could Explain Discrepancies between Viral Load and CD4+ Cell Response in Human Immunodeficiency Virusâ€"Infected Patients Receiving Antiretroviral Therapy. Clinical Infectious Diseases, 2000, 30, 392-394.	5.8	30
111	Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. European Respiratory Journal, 2014, 43, 166-177.	6.7	30
112	Standard vaccines increase HIV-1 transcription during antiretroviral therapy. Aids, 2016, 30, 2289-2298.	2.2	30
113	Sexually transmitted infections in young people and factors associated with HIV coinfection: an observational study in a large city. BMJ Open, 2019, 9, e027245.	1.9	30
114	Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. Journal of Antimicrobial Chemotherapy, 2021, 76, 3296-3302.	3.0	30
115	Redistribution of FOXP3-Positive Regulatory T Cells From Lymphoid Tissues to Peripheral Blood in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 529-537.	2.1	28
116	HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. Clinical Infectious Diseases, 2017, 64, ciw833.	5.8	28
117	New challenges in therapeutic vaccines against HIV infection. Expert Review of Vaccines, 2017, 16, 587-600.	4.4	28
118	An integral care telemedicine system for HIV/AIDS patients. International Journal of Medical Informatics, 2006, 75, 638-642.	3.3	27
119	Effect of Genetic Variants of CCR2 and CCL2 on the Natural History of HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 132-138.	2.1	27
120	Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms. Aids, 2012, 26, 1829-1834.	2.2	27
121	Clarithromycin-Induced Acute Psychoses in Peptic Ulcer Disease. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18, 70-71.	2.9	26
122	Influence of a Vaccination Schedule on Viral Load Rebound and Immune Responses in Successfully Treated HIV-Infected Patients. AIDS Research and Human Retroviruses, 2009, 25, 1249-1259.	1.1	26
123	Adenosine deaminase enhances Tâ€cell response elicited by dendritic cells loaded with inactivated HIV. Immunology and Cell Biology, 2009, 87, 634-639.	2.3	26
124	Analysis of transmitted drug resistance in Spain in the years 2007â€"2010 documents a decline in mutations to the non-nucleoside drug class. Clinical Microbiology and Infection, 2012, 18, E485-E490.	6.0	26
125	Polymorphisms in the interleukin-4 receptor Î± chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. Immunogenetics, 2005, 57, 644-654.	2.4	25
126	Immunological dysfunction in HIVâ€1â€infected individuals caused by impairment of adenosine deaminaseâ€induced costimulation of Tâ€cell activation. Immunology, 2009, 128, 393-404.	4.4	25

#	Article	IF	Citations
127	Factors associated with the immune response to hepatitis A vaccination in HIV-infected patients in the era of highly active antiretroviral therapy. Vaccine, 2013, 31, 3668-3674.	3.8	25
128	Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix. Vaccines, 2019, 7, 209.	4.4	25
129	Effect of TNF-Î± genetic variants and CCR5Î”32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards. BMC Medical Genetics, 2010, 11, 63.	2.1	24
130	Post-Exposure Prophylaxis for HIV Infection: A Clinical Trial Comparing Lopinavir/Ritonavir versus Atazanavir Each with Zidovudine/Lamivudine. Antiviral Therapy, 2012, 17, 337-346.	1.0	24
131	The EuroSIDA study: 25 years of scientific achievements. HIV Medicine, 2020, 21, 71-83.	2.2	24
132	A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART. PLoS ONE, 2015, 10, e0141456.	2.5	24
133	Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort. PLoS ONE, 2015, 10, e0145701.	2.5	24
134	A butterfly vertebra or a wedge fracture?. International Orthopaedics, 1993, 17, 7-10.	1.9	23
135	Endothelial Cell Activation in Muscle Biopsy Samples Is Related to Clinical Severity in Human Cerebral Malaria. Journal of Infectious Diseases, 1999, 179, 475-483.	4.0	23
136	Long-term Clinical Follow-up, without Antiretroviral Therapy, of Patients with Chronic HIV-1 Infection with Good Virological Response to Structured Treatment Interruption. Clinical Infectious Diseases, 2004, 39, 569-574.	5.8	23
137	Proteomic Profile Associated With Loss of Spontaneous Human Immunodeficiency Virus Type 1 Elite Control. Journal of Infectious Diseases, 2019, 219, 867-876.	4.0	23
138	Comparison of T-Cell Subsets' Reconstitution After 12 Months of Highly Active Antiretroviral Therapy Initiated During Early Versus Advanced States of HIV Disease. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 296-305.	2.1	22
139	Biphasic decline of CD4 cell count during scheduled treatment interruptions. Aids, 2005, 19, 439-441.	2.2	22
140	Impact of Î±-defensins1â€“3 on the maturation and differentiation of human monocyte-derived DCs. Concentration-dependent opposite dual effects. Clinical Immunology, 2009, 131, 374-384.	3.2	22
141	Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice. Vaccine, 2012, 30, 3703-3709.	3.8	22
142	IL28B Single-Nucleotide Polymorphism rs12979860 Is Associated With Spontaneous HIV Control in White Subjects. Journal of Infectious Diseases, 2013, 207, 651-655.	4.0	22
143	High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/Î¼l and opportunistic diseases: the EfaVIP Study (Efavirenz in Very) Tj ETQq1 1 0.784314 rgBT /Overlo	4.3	22
144	MicroRNA Profile in CD8+ T-Lymphocytes from HIV-Infected Individuals: Relationship with Antiviral Immune Response and Disease Progression. PLoS ONE, 2016, 11, e0155245.	2.5	22

#	Article	IF	Citations
145	Transmission of Hepatitis C Virus by Discarded-Needle Injury. Clinical Infectious Diseases, 2005, 41, 129-130.	5.8	21
146	Prevalence of dihydropteroate synthase genotypes before and after the introduction of combined antiretroviral therapy and their influence on the outcome of Pneumocystis pneumonia in HIV-1â€“infected patients. Diagnostic Microbiology and Infectious Disease, 2010, 68, 60-65.	1.8	21
147	Comparison of two <scp>HIV</scp> testing strategies in primary care centres: indicatorâ€conditionâ€guided testing vs. testing of those with nonâ€indicator conditions. HIV Medicine, 2013, 14, 33-37.	2.2	21
148	Adenosine Deaminase Enhances the Immunogenicity of Human Dendritic Cells from Healthy and HIV-Infected Individuals. PLoS ONE, 2012, 7, e51287.	2.5	21
149	Inflammatory Responses in Blood Samples of Human Immunodeficiency Virus-Infected Patients with Pulmonary Infections. Vaccine Journal, 2004, 11, 608-614.	3.1	20
150	Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2006, 24, 238-244.	0.5	20
151	Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naÃ¯ve HIV-infected patients (CoRIS). Antiviral Research, 2011, 89, 19-25.	4.1	20
152	Influence of Episodes of Intermittent Viremia (â€œBlipsâ€) on Immune Responses and Viral Load Rebound in Successfully Treated HIV-Infected Patients. AIDS Research and Human Retroviruses, 2013, 29, 68-76.	1.1	20
153	Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses. Vaccine, 2014, 32, 6266-6276.	3.8	20
154	Adenosine deaminase regulates Treg expression in autologous T cell-dendritic cell cocultures from patients infected with HIV-1. Journal of Leukocyte Biology, 2016, 99, 349-359.	3.3	20
155	Real-life use of remdesivir in hospitalized patients with COVID-19. Revista Espanola De Quimioterapia, 2021, 34, 136-140.	1.3	20
156	Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. PLoS ONE, 2017, 12, e0186602.	2.5	20
157	Comparison of Immunologic Restoration and Virologic Response in Plasma, Tonsillar Tissue, and Cerebrospinal Fluid in HIV-1â€“Infected Patients Treated With Double Versus Triple Antiretroviral Therapy in Very Early Stages: The Spanish Earth-2 Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 26-35.	2.1	19
158	Immunologic Reconstitution After 1 Year of Highly Active Antiretroviral Therapy, With or Without Protease Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 429-434.	2.1	19
159	Lymphoid Tissue Collagen Deposition in HIV-Infected Patients Correlates With the Imbalance Between Matrix Metalloproteinases and Their Inhibitors. Journal of Infectious Diseases, 2011, 203, 810-813.	4.0	19
160	Optimal timing for initiation of highly active antiretroviral therapy in treatment-naÃ¯ve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort. Clinical Microbiology and Infection, 2013, 19, 646-653.	6.0	19
161	Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004â€“2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions. PLoS ONE, 2014, 9, e116226.	2.5	19
162	Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers. BMC Medicine, 2018, 16, 30.	5.5	19

#	Article	IF	Citations
163	Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infection. Aids, 1998, 12, 1285-1289.	2.2	18
164	Does short-term virologic failure translate to clinical events in antiretroviral-naÃ¯ve patients initiating antiretroviral therapy in clinical practice?. Aids, 2008, 22, 2481-2492.	2.2	18
165	Restoration of T Cell Responses to Toxoplasma gondii after Successful Combined Antiretroviral Therapy in Patients with AIDS with Previous Toxoplasmic Encephalitis. Clinical Infectious Diseases, 2011, 52, 662-670.	5.8	18
166	All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997â€“2010. BMC Infectious Diseases, 2013, 13, 382.	2.9	18
167	Evolution of Broadly Cross-Reactive HIV-1-Neutralizing Activity: Therapy-Associated Decline, Positive Association with Detectable Viremia, and Partial Restoration of B-Cell Subpopulations. Journal of Virology, 2013, 87, 12227-12236.	3.4	18
168	The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity. Retrovirology, 2017, 14, 50.	2.0	18
169	Extremely low viral reservoir in treated chronically HIV-1-infected individuals. EBioMedicine, 2020, 57, 102830.	6.1	18
170	Non-myeloablative hematopoietic stem cell transplantation in the treatment of severe idiopathic CD4+ lymphocytopenia. European Journal of Haematology, 2011, 87, 87-91.	2.2	17
171	Clinically Relevant Transmitted Drug Resistance to First Line Antiretroviral Drugs and Implications for Recommendations. PLoS ONE, 2014, 9, e90710.	2.5	17
172	Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation. Journal of the International AIDS Society, 2014, 17, 19246.	3.0	17
173	Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation. Nanomedicine, 2014, 9, 2683-2702.	3.3	17
174	Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: a cross-sectional analysis. BMC Nephrology, 2017, 18, 58.	1.8	17
175	Estimating the HIV undiagnosed population in Catalonia, Spain: descriptive and comparative data analysis to identify differences in MSM stratified by migrant and Spanish-born population. BMJ Open, 2018, 8, e018533.	1.9	17
176	Comparison of T-Cell Subsets' Reconstitution After 12 Months of Highly Active Antiretroviral Therapy Initiated During Early Versus Advanced States of HIV Disease. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 296-305.	2.1	16
177	Lymphoid tissue viral burden and duration of viral suppression in plasma. Aids, 2001, 15, 1477-1482.	2.2	16
178	Failure of Cetirizine to Prevent Nevirapine-Associated Rash. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1276-1281.	2.1	16
179	Pharmacokinetics and Pharmacodynamics of Low Dose Mycophenolate Mofetil in HIV-Infected Patients Treated with Abacavir, Efavirenz and Nelfinavir. Clinical Pharmacokinetics, 2005, 44, 525-538.	3.5	16
180	Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV Type 1-Infected Patients Using a Nonnucleoside Reverse Transcriptase Inhibitor-Based or a Boosted Protease Inhibitor-Based Antiretroviral Regimen: Three-Year Results (The Advanz Trial): A Randomized, Controlled Trial. AIDS Research and Human Retroviruses, 2010, 26, 747-757.	1.1	16

#	Article	IF	Citations
181	Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis. PLoS ONE, 2011, 6, e26009.	2.5	16
182	A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. Journal of Antimicrobial Chemotherapy, 2016, 71, 1987-1993.	3.0	16
183	Impact of long-term antiretroviral therapy interruption and resumption on viral reservoir in HIV-1 infected patients. Aids, 2017, 31, 1895-1897.	2.2	16
184	In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?. Viruses, 2021, 13, 501.	3.3	16
185	Quinine induced lupus-like syndrome and cardiolipin antibodies.. Annals of the Rheumatic Diseases, 1996, 55, 559-560.	0.9	15
186	Immunological and virological factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection. Aids, 2002, 16, 1761-1765.	2.2	15
187	Immunologic Reconstitution After 1 Year of Highly Active Antiretroviral Therapy, With or Without Protease Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 429-434.	2.1	15
188	Highly Active Antiretroviral Therapy (HAART) Modifies the Incidence and Outcome of Visceral Leishmaniasis in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 30, 364-366.	2.1	15
189	Dynamics of T Cells Subsets and Lymphoproliferative Responses During Structured Treatment Interruption Cycles and After Definitive Interruption of HAART in Early Chronic HIV Type-1-Infected Patients. AIDS Research and Human Retroviruses, 2006, 22, 657-666.	1.1	15
190	Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients. Chest, 2017, 152, 295-303.	0.8	15
191	Off the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV. Journal of Controlled Release, 2021, 330, 1016-1033.	9.9	15
192	Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial. Trials, 2021, 22, 808.	1.6	15
193	Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients. Infection, 2022, 50, 1321-1328.	4.7	15
194	Persistence of Novel First-Line Antiretroviral Regimes in a Cohort of HIV-Positive Subjects, Coris 2008â€“2010. Antiviral Therapy, 2013, 18, 161-170.	1.0	14
195	Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1â€“Infected Patients Starting Efavirenz, Lopinavirâ€“Ritonavir, or Atazanavirâ€“Ritonavir Plus Tenofovir/Emtricitabine. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 206-215.	2.1	14
196	HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial. Npj Vaccines, 2019, 4, 25.	6.0	14
197	Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count. Journal of Microbiology, Immunology and Infection, 2019, 52, 667-671.	3.1	14
198	Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men. Clinical Microbiology and Infection, 2018, 24, 540-545.	6.0	13

#	Article	IF	Citations
199	The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia. Archivos De Bronconeumologia, 2021, 57, 79-82.	0.8	13
200	Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. PLoS ONE, 2017, 12, e0184929.	2.5	13
201	Immunosuppressive drugs as an adjuvant to HIV treatment. Journal of Antimicrobial Chemotherapy, 2004, 53, 415-417.	3.0	12
202	Laryngeal squamous cell carcinoma in HIVâ€positive patients: lack of association with human papillomavirus infection. HIV Medicine, 2009, 10, 634-639.	2.2	12
203	The reconstitution of the thymus in immunosuppressed individuals restores CD4â€specific cellular and humoral immune responses. Immunology, 2011, 133, 318-328.	4.4	12
204	Compliance with national guidelines for <scp>HIV</scp> treatment and its association with mortality and treatment outcome: a study in a <scp>S</scp>panish cohort. HIV Medicine, 2014, 15, 86-97.	2.2	12
205	Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. Journal of Antimicrobial Chemotherapy, 2017, 72, 2857-2861.	3.0	12
206	Continued propagation of the CRF19_cpx variant among HIV-positive MSM patients in Spain. Journal of Antimicrobial Chemotherapy, 2018, 73, 1031-1038.	3.0	12
207	Postâ€exposure prophylaxis for HIV infection in sexual assault victims. HIV Medicine, 2020, 21, 43-52.	2.2	12
208	Adherence to a Supplemented Mediterranean Diet Drives Changes in the Gut Microbiota of HIV-1-Infected Individuals. Nutrients, 2021, 13, 1141.	4.1	12
209	Redistribution of FOXP3-positive regulatory T cells from lymphoid tissues to peripheral blood in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 529-37.	2.1	12
210	Predictive Factors Influencing Peak Viral Load Drop in Response to Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral-Naive HIV-1-Infected Patients. Journal of Acquired Immune Deficiency Syndromes, 1998, 19, 55-60.	0.3	11
211	Immune modulators and treatment interruption. Current Opinion in HIV and AIDS, 2008, 3, 124-130.	3.8	11
212	Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. International Journal of Tuberculosis and Lung Disease, 2014, 18, 700-708.	1.2	11
213	Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007â€“2012). Clinical Microbiology and Infection, 2015, 21, 105.e1-105.e5.	6.0	11
214	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 377-383.	0.5	11
215	Indicator condition-guided HIV testing with an electronic prompt in primary healthcare: a before and after evaluation of an intervention. Sexually Transmitted Infections, 2019, 95, 238-243.	1.9	11
216	Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen. Vaccines, 2021, 9, 959.	4.4	11

#	Article	IF	Citations
217	C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19. Scientific Reports, 2022, 12, 5250.	3.3	11
218	Streptococcal myositis as a complication of juvenile dermatomyositis. Neuromuscular Disorders, 1991, 1, 375-377.	0.6	10
219	Introduction of HIV type 1 non-B subtypes into Eastern Andalusia through immigration. Journal of Medical Virology, 2003, 70, 10-13.	5.0	10
220	HIV-1 Upregulates Intercellular Adhesion Molecule-1 Gene Expression in Lymphoid Tissue of Patients With Chronic HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 268-274.	2.1	10
221	Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine. Vaccine, 2009, 27, 6166-6178.	3.8	10
222	Generation and Characterization of a Defective HIV-1 Virus as an Immunogen for a Therapeutic Vaccine. PLoS ONE, 2012, 7, e48848.	2.5	10
223	TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality. BioMed Research International, 2013, 2013, 1-9.	1.9	10
224	Detection of HIV-1-specific T-cell immune responses in highly HIV-exposed uninfected individuals by in-vitro dendritic cell co-culture. Aids, 2015, 29, 1309-1318.	2.2	10
225	Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression. Frontiers in Immunology, 2017, 8, 836.	4.8	10
226	Cholesterol efflux responds to viral load and CD4 counts in HIV+ patients and is dampened in HIV exposed. Journal of Lipid Research, 2018, 59, 2108-2115.	4.2	10
227	Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients. PLoS ONE, 2019, 14, e0220459.	2.5	10
228	High rates of longâ€term progression in HIVâ€1â€positive elite controllers. Journal of the International AIDS Society, 2021, 24, e25675.	3.0	10
229	Platform encounters: A study of digitised patient followâ€up in HIV care. Sociology of Health and Illness, 2021, 43, 1117-1135.	2.1	10
230	Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. Revista Espanola De Quimioterapia, 2021, 34, 238-244.	1.3	10
231	Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antiviral Therapy, 2005, 10, 423-9.	1.0	10
232	Genotypic and Phenotypic Resistance Patterns in Early-Stage HIV-1-Infected Patients Failing Initial Therapy with Stavudine, Didanosine and Nevirapine. Antiviral Therapy, 2002, 7, 283-287.	1.0	10
233	Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines. Vaccine, 2011, 29, 5711-5724.	3.8	9
234	â€˜Functional cureâ€™ of HIV infection: the role of immunotherapy. Immunotherapy, 2012, 4, 245-248.	2.0	9

#	Article	IF	Citations
235	Effects on Innate Immunity of a Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection. Viral Immunology, 2012, 25, 37-44.	1.3	9
236	Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease. Aids, 2015, 29, 1493-1504.	2.2	9
237	Increased expression with differential subcellular location of cytidine deaminase APOBEC3G in human CD4 + Tâ€cell activation and dendritic cell maturation. Immunology and Cell Biology, 2016, 94, 689-700.	2.3	9
238	A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. Journal of Antimicrobial Chemotherapy, 2016, 71, 1982-1986.	3.0	9
239	The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults. Medicine (United States), 2016, 95, e2673.	1.0	9
240	Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virusâ€"Infected Adult Patients: A Matched Case-Control Study. Clinical Infectious Diseases, 2018, 67, 958-961.	5.8	9
241	Establishing a hepatitis C continuum of care among <scp>HIV</scp>/hepatitis C virusâ€coinfected individuals in Euro<scp>SIDA</scp>. HIV Medicine, 2019, 20, 264-273.	2.2	9
242	Use of RT-Defective HIV Virions: New Tool to Evaluate Specific Response in Chronic Asymptomatic HIV-Infected Individuals. PLoS ONE, 2013, 8, e58927.	2.5	9
243	Immune Restoration in HIV-Positive, Antiretroviral-Naive Patients after 1 Year of Zidovudine/Lamivudine plus Nelfinavir or Nevirapine. Antiviral Therapy, 2004, 9, 197-204.	1.0	9
244	Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption. Journal of Antimicrobial Chemotherapy, 2008, 63, 184-188.	3.0	8
245	Assessment of migration of HIV-1-loaded dendritic cells labeled with¹¹¹In-oxine used as a therapeutic vaccine in HIV-1-infected patients. Immunotherapy, 2009, 1, 347-354.	2.0	8
246	Therapeutic HIV vaccines: Prior setbacks, current advances, and future prospects. Vaccine, 2014, 32, 5540-5545.	3.8	8
247	Immunological Function Restoration with Lopinavir/Ritonavir Versus Efavirenz Containing Regimens in HIV-Infected Patients: A Randomized Clinical Trial. AIDS Research and Human Retroviruses, 2014, 30, 425-433.	1.1	8
248	A Role for Scavenger-like Lymphocyte Receptor CD6 in HIV-1 Viral Infection. AIDS Research and Human Retroviruses, 2014, 30, A49-A50.	1.1	8
249	Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. PLoS ONE, 2018, 13, e0208345.	2.5	8
250	Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response. Vaccines, 2020, 8, 442.	4.4	8
251	Impact of Transcriptome and Gut Microbiome on the Response of HIV-1 Infected Individuals to a Dendritic Cell-Based HIV Therapeutic Vaccine. Vaccines, 2021, 9, 694.	4.4	8
252	Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review. BMC Public Health, 2021, 21, 1596.	2.9	8

#	Article	IF	Citations
253	Predictors of progression in chronically infected naive patients with plasma viraemia below 5000 copies/ml and CD4 T lymphocytes greater than 500 Ã— 106/l. Aids, 2001, 15, 131-133.	2.2	8
254	Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients. International Journal of Tuberculosis and Lung Disease, 2013, 17, 198-206.	1.2	7
255	Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults. Clinical Microbiology and Infection, 2015, 21, 104.e1-104.e5.	6.0	7
256	Utility of Systematic Isolation of immune cell subsets from HIV-infected individuals for miRNA profiling. Journal of Immunological Methods, 2017, 442, 12-19.	1.4	7
257	Experience with the use of siltuximab in patients with SARS-CoV-2 infection. Revista Espanola De Quimioterapia, 2021, 34, 337-341.	1.3	7
258	Metabolic and Immunological Effects of Antiretroviral Agents in Healthy Individuals Receiving Post-Exposure Prophylaxis. Antiviral Therapy, 2002, 7, 195-197.	1.0	7
259	Predictors of Tonsillar Tissue HIV-1 Viral Burden at Baseline and after 1 Year of Antiretroviral Therapy. Antiviral Therapy, 2003, 8, 635-637.	1.0	7
260	Utilization of healthcare services by people living with HIV/AIDS in Europe. International Journal of STD and AIDS, 2000, 11, 784-789.	1.1	6
261	Clinicoimmunological Progression and Response to Treatment of Long-Term Nonprogressor HIVâ€“Hepatitis C Virus-Coinfected Patients. AIDS Research and Human Retroviruses, 2007, 23, 863-867.	1.1	6
262	Short Communication: Natural Killer Cells and Expression of KIR Receptors in Chronic HIV Type 1-Infected Patients after Different Strategies of Structured Therapy Interruption. AIDS Research and Human Retroviruses, 2008, 24, 1485-1495.	1.1	6
263	Effects of highly active antiretroviral therapy on vaccineâ€induced humoral immunity in HIVâ€infected adults. HIV Medicine, 2010, 11, 535-539.	2.2	6
264	Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavirâ€boosted protease inhibitorâ€based versus a nonnucleoside reverse transcriptase inhibitorâ€based firstâ€line regimen. HIV Medicine, 2014, 15, 547-556.	2.2	6
265	Boosted Lopinavirâ€“ Versus Boosted Atazanavirâ€“Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases, 2015, 60, 1262-1268.	5.8	6
266	Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination. Aids, 2016, 30, 553-562.	2.2	6
267	Determinants and Outcomes of Late Presentation of HIV Infection in Migrants in Catalonia, Spain: PISCIS Cohort 2004â€“2016. Journal of Immigrant and Minority Health, 2019, 21, 920-930.	1.6	6
268	Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study. Frontiers in Immunology, 2020, 11, 586124.	4.8	6
269	EmERGE mHealth Platform: Implementation and Technical Evaluation of a Digital Supported Pathway of Care for Medically Stable HIV. International Journal of Environmental Research and Public Health, 2021, 18, 3156.	2.6	6
270	Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial. HIV Medicine, 2021, 22, 674-681.	2.2	6

#	Article	IF	Citations
271	High rate of long-term clinical events after antiretroviral therapy resumption in HIV-positive patients exposed to antiretroviral therapy interruption. Aids, 2021, 35, 2463-2468.	2.2	6
272	Measles inclusion body encephalitis. , 2020, 39, 148-151.		6
273	A Home Integral Telecare System for HIV/AIDS Patients. Studies in Health Technology and Informatics, 2005, 114, 23-9.	0.3	6
274	Altered Tâ€cell subset distribution in the viral reservoir in HIVâ€1â€infected individuals with extremely low proviral DNA (LoViReTs). Journal of Internal Medicine, 2022, 292, 308-320.	6.0	6
275	Changes in HIV-1 RNA Viral Load Following Tuberculin Skin Test. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 398-399.	0.3	5
276	Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection. Clinical Infectious Diseases, 2016, 62, 1578-1585.	5.8	5
277	Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. Lancet HIV,the, 2019, 6, e334-e340.	4.7	5
278	Virological outcome measures during analytical treatment interruptions in chronic HIV-1 infected patients. Open Forum Infectious Diseases, 2019, 6, ofz485.	0.9	5
279	Measuring empowerment among people living with HIV: a systematic review of available measures and their properties. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 798-802.	1.2	5
280	Feasibility of using monocyte-derived dendritic cells obtained from cryopreserved cells for DC-based vaccines. Journal of Immunological Methods, 2021, 498, 113133.	1.4	5
281	Evaluation of the Roche COBASÂ® TaqManÂ® HIV-1 test for quantifying HIV-1 RNA in infected cells and lymphoid tissue. Journal of Virological Methods, 2011, 174, 69-76.	2.1	4
282	Reasons for Not Participating in a Phase 1 Preventive HIV Vaccine Study in a Resource-Rich Country. AIDS Patient Care and STDs, 2012, 26, 379-382.	2.5	4
283	Effects of Different Antigenic Stimuli on Thymic Function and Interleukin-7/CD127 System in Patients with Chronic HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 466-472.	2.1	4
284	Predictive Factors for HIV Seroconversion Among Individuals Attending a Specialized Center After an HIV Risk Exposure: A Caseâ€“Control Study. AIDS Research and Human Retroviruses, 2016, 32, 1016-1021.	1.1	4
285	Multiple imputation approach for intervalâ€censored time to HIV RNA viral rebound within a mixed effects Cox model. Biometrical Journal, 2019, 61, 299-318.	1.0	4
286	HCV reinfection after HCV therapy among HIV/HCVâ€coinfected individuals in Europe. HIV Medicine, 2022, 23, 684-692.	2.2	4
287	Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor. Aids, 2005, 19, 829-831.	2.2	3
288	Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy. Immunologic Research, 2016, 64, 1207-1215.	2.9	3

#	Article	IF	Citations
289	Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3â€year retrospective cohort study. Transplant Infectious Disease, 2017, 19, e12724.	1.7	3
290	High Plasma Levels of sTNF-R1 and CCL11 Are Related to CD4+ T-Cells Fall in Human Immunodeficiency Virus Elite Controllers With a Sustained Virologic Control. Frontiers in Immunology, 2018, 9, 1399.	4.8	3
291	Differential miRNA plasma profiles associated with the spontaneous loss of HIVâ€1 control: miRâ€199aâ€3p and its potential role as a biomarker for quick screening of elite controllers. Clinical and Translational Medicine, 2021, 11, e474.	4.0	3
292	Association of Transcriptomic Signatures of Inflammatory Response with Viral Control after Dendritic Cell-Based Therapeutic Vaccination in HIV-1 Infected Individuals. Vaccines, 2021, 9, 799.	4.4	3
293	Gustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia: a prospective study. BMJ Open, 2021, 11, e040775.	1.9	3
294	Positive Outcomes: Validity, reliability and responsiveness of a novel personâ€centred outcome measure for people with HIV. HIV Medicine, 2022, 23, 673-683.	2.2	3
295	Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine. Antiviral Therapy, 2004, 9, 197-204.	1.0	3
296	Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon Î±-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial. Frontiers in Immunology, 2021, 12, 767370.	4.8	3
297	Endocytosis by mature muscle cells of aggregates of parasitised erythrocytes and macrophages in severe malaria. Lancet, The, 1996, 347, 1550-1551.	13.7	2
298	Retrospective analysis of antiretroviral HIV treatment success based on medical history or guided by the reverse hybridisation LiPA HIV genotyping system. Journal of Medical Virology, 2004, 73, 151-157.	5.0	2
299	Inmunoterapia y vacunas terapÃ©uticas en la infecciÃ³n por VIH. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2005, 23, 84-94.	0.5	2
300	Polymorphisms in the 3â€² untranslated region of the fractalkine (CX3CL1) gene and the risk of HIV-1 infection and disease progression. Aids, 2007, 21, 891-893.	2.2	2
301	Local barrier dysfunction identified by confocal laser endomicroscopy predicts bacterial translocation in HIV infection. Aids, 2020, 34, 328-331.	2.2	2
302	Persistent HIVâ€controllers are more prone to spontaneously clear HCV: a retrospective cohort study. Journal of the International AIDS Society, 2020, 23, e25607.	3.0	2
303	A Classifier to Predict Viral Control After Antiretroviral Treatment Interruption in Chronic HIV-1â€“Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 479-485.	2.1	2
304	Network metaâ€analysis of postâ€exposure prophylaxis randomized clinical trials. HIV Medicine, 2021, 22, 218-224.	2.2	2
305	Efficiency of the EmERGE Pathway to provide continuity of care for Spanish people living with medically stable HIV. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2022, 40, 388-395.	0.5	2
306	Clinical Characteristics and Outcome of Bloodstream Infections in HIV-Infected Patients with Cancer and Febrile Neutropenia: A Caseâ€“Control Study. Infectious Diseases and Therapy, 2021, 10, 955-970.	4.0	2

#	Article	IF	Citations
307	Predictors of tonsillar tissue HIV-1 viral burden at baseline and after 1 year of antiretroviral therapy. Antiviral Therapy, 2003, 8, 635-7.	1.0	2
308	The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. HIV Medicine, 2022, 23, 585-598.	2.2	2
309	Editorial: Advances in T Cell Therapeutic Vaccines for HIV. Frontiers in Immunology, 2022, 13, 905836.	4.8	2
310	Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study. Infectious Diseases and Therapy, 2022, 11, 1243-1251.	4.0	2
311	Similar HIV-1 evolution and immunological responses at 10 years despite several therapeutic strategies and host HLA Types. Journal of Medical Virology, 2004, 73, 495-501.	5.0	1
312	Immunotherapy and therapeutic vaccines in HIV infection. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2005, 23, 95-104.	0.5	1
313	Fusarium keratoplasticum infection in an HIV-infected patient. International Journal of STD and AIDS, 2018, 29, 1039-1042.	1.1	1
314	Cholangitis and pulmonary nodules in a clinical presentation of syphilis in an HIV-infected patient. International Journal of STD and AIDS, 2019, 30, 820-824.	1.1	1
315	Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B. Vaccines, 2019, 7, 178.	4.4	1
316	Temporal Data Mining of HIV Registries: Results from a 25 Years Follow-Up. Lecture Notes in Computer Science, 2009, , 56-60.	1.3	1
317	Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study. , 2017, , .		1
318	Shared Care Unit: a new model of coordinating HIV care between Primary Settings and Hospital. International Journal of Integrated Care, 2016, 16, 200.	0.2	1
319	Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. Open Forum Infectious Diseases, 2020, 7, ofaa470.	0.9	1
320	Immunotherapy and therapeutic vaccines in HIV infection. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2005, 23 Suppl 2, 84-104.	0.5	1
321	Cellular immune responses and changes in VL after a Dendritic Cells (DC)-based therapeutic vaccine in cART treated chronic HIV-infected patients with CD4 T cells above 450/mm. Retrovirology, 2012, 9, O42.	2.0	0
322	Monocyte-derived DC Electroporated with mRNAs Encoding Both Specific HIV Antigens and DC Adjuvants Are Able to Improve T-cell Functionality. AIDS Research and Human Retroviruses, 2014, 30, A194-A194.	1.1	0
323	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 377-383.	0.3	0
324	Pleural effusion as a manifestation of a Cryptococcal infection in an HIV patient. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2021, 39, 524-524.	0.5	0

#	Article	IF	Citations
325	Pulmonary Infection Caused by Mycobacterium malmoense in a Chronic HIV-Infected Individual Participating in a Therapeutic Vaccine Trial. Vaccines, 2021, 9, 1103.	4.4	0
326	Structured therapy interruptions (STIs): lessons from a therapeutic strategy. , 2004, , 115-126.		0
327	Highly Efficient Autologous HIV-1 Isolation by Coculturing Macrophage With Enriched CD4+ T Cells From HIV-1 Patients. Frontiers in Virology, 2022, 2, .	1.4	0
328	Pleural effusion as a manifestation of a Cryptococcal infection in an HIV patient. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2021, 39, 524-526.	0.3	0